HC Wainwright Brokers Increase Earnings Estimates for ALDX

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Investment analysts at HC Wainwright increased their FY2029 earnings estimates for shares of Aldeyra Therapeutics in a research report issued to clients and investors on Monday, May 19th. HC Wainwright analyst M. Caufield now expects that the biotechnology company will post earnings of $1.10 per share for the year, up from their previous estimate of $1.00. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share.

Several other brokerages have also issued reports on ALDX. StockNews.com upgraded shares of Aldeyra Therapeutics to a “sell” rating in a report on Wednesday. BTIG Research lowered their price objective on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, April 7th.

Aldeyra Therapeutics Price Performance

ALDX stock opened at $2.25 on Tuesday. Aldeyra Therapeutics has a 52-week low of $1.14 and a 52-week high of $7.20. The business has a fifty day moving average of $3.29 and a two-hundred day moving average of $4.67. The stock has a market cap of $134.77 million, a price-to-earnings ratio of -2.32 and a beta of 0.92. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.08.

Insider Buying and Selling at Aldeyra Therapeutics

In related news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of Aldeyra Therapeutics stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total value of $4,828,000.00. Following the completion of the transaction, the insider now owns 5,875,851 shares in the company, valued at approximately $8,343,708.42. The trade was a 36.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 9.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Aldeyra Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Hsbc Holdings PLC purchased a new position in Aldeyra Therapeutics during the 4th quarter worth approximately $52,000. Balyasny Asset Management L.P. acquired a new position in Aldeyra Therapeutics in the 4th quarter valued at about $56,000. Capital Advisors Wealth Management LLC purchased a new stake in Aldeyra Therapeutics during the 1st quarter valued at approximately $62,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Aldeyra Therapeutics during the 1st quarter worth approximately $63,000. Finally, Catalyst Funds Management Pty Ltd grew its stake in shares of Aldeyra Therapeutics by 2,083.3% in the 4th quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 12,500 shares during the last quarter. Hedge funds and other institutional investors own 59.71% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.